Tag: Ayala Pharmaceuticals

September 30, 2019 Off

Ayala Pharmaceuticals encouraged with phase 2 clinical trial in patients with recurrent/metastatic adenoid cystic carcinoma

– 22% Response Rate; 61% Disease Control Observed – REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical…

May 20, 2019 Off

Ayala Pharmaceuticals’ preclinical data supports clinical development of AL101 in TripleNegative Breast Cancer (TNBC) tumors bearing Notch mutation

By BusinessWire

– Ongoing Phase 2 ACCURACY study to explore AL101 and its effect on tumor growth inhibition in people with Adenoid…